USP and Public Policy
Left
Refine Your Search
USP Comment Letter: Submitted to Office of the United States Trade Representative on Comments on Promoting Supply Chain Resilience (USTR-20240002) (2024)
Learn More
USP Global Public Policy Position: Fostering the Use of Novel Excipients in Drug Products; Published 2024.
Learn More
USP Global Policy Position: Excipients: A Blind Spot in Ensuring Medicine Quality and Supply Chain Resilience; Published 2024
Learn More
The USP submits comments to the Draft Guidance for Industry; Dietary Supplements: New Dietary Ingredient Notifications and Related Issues (“Guidance”) published by the Food and Drug Administration (…
Learn More
Identifying and addressing vulnerabilities in the upstream pharmaceutical supply chain are essential to mitigating and preventing drug shortages and to ensuring patients have access to the critical…
Learn More